دگارلیکس CAS:214766-78-6

دگارلیکس, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer.Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management of advanced prostate cancer. Degarelix has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. This induces a fast and profound reduction in luteinizing hormone (LH), follicle-stimulating hormone (FSH) and in turn, testosterone suppression.

Degarelix is studied for use as a chemical castration agent on sex offenders in Sweden.A study published on April 29, 2020, in JAMA Psychiatry demonstrated a reduced the risk score for committing child sexual abuse in men with pedophilic disorder two weeks after initial injection.